ArticleAmerican journal of cancer research2020
Livin promotes tumor progression through YAP activation in ovarian cancer.
Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- A novel function of STARD7: its tumor-promoting role involves the activation of NF-κB signaling pathway in ovarian cancer.Human cell · 2025Article
- MZB1 regulates the immune microenvironment and inhibits ovarian cancer cell migration.Open medicine (Warsaw, Poland) · 2025Article
- New Horizons in Cancer Progression and Metastasis:Biomedicines · 2024Review
- PI3K/Akt/YAP signaling promotes migration and invasion of DLD-1 colorectal cancer cells.Oncology letters · 2022Article
- Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies.Frontiers in oncology · 2022Review
- Ultrasound-Targeted Microbubble Destruction-Mediated Inhibition of Livin Expression Accelerates Ovarian Cancer Cell Apoptosis.Genetics research · 2021Article
- Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer.Journal of Cancer · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a gynecological malignant tumor with a high morbidity. Livin is a novel member of the inhibitor of apoptosis protein family, which is expressed in various malignant tumors and is suggested to be a poor prognostic factor. However, the prognostic significance of Livin and the molecular mechanisms by which Livin promotes ovarian cancer progression are poorly understood. In this study, the upregulation of Livin was confirmed both in primary specimens from ovarian cancer patients and in ovarian cancer cell lines compared to normal controls
Indexed as
Identifiers
33163264PMC7642671W3105519357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.